Organicell Regenerative Medicine, Inc., a clinical-stage biopharmaceutical company, focuses on the development of biological therapeutics for the treatment of degenerative diseases and regenerative medicines. Its lead product candidate is Zofin, an acellular biologic therapeutic derived from perinatal sources, which is in Phase I/II clinical trial to treat COVID-19, chronic obstructive pulmonary disease, and knee osteoarthritis. The company also provides Patient Pure X, an autologous blood-derived biologic technology, that is placed in the body for exosomes the cascade of cellular reprogramming and tissue repair. It has a research and development agreement with the Centers for Disease Control and Prevention to determine the anti-inflammatory and anti-infective effectiveness of Zofin in experimental models of influenza infection; and an agreement with Oklahoma State University to evaluate Zofin for the treatment of respiratory diseases caused by virus infections of pandemic potential. The company was formerly known as Biotech Products Services and Research, Inc. and changed its name to Organicell Regenerative Medicine, Inc. in June 2018. Organicell Regenerative Medicine, Inc. was incorporated in 2011 and is headquartered in Fort Lauderdale, Florida.